ReviewTransfusion medicine reviews2019
Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.
Review in Transfusion medicine reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Treatment of Acute Hemolytic Transfusion Reaction due to ABO-Incompatible Red Blood Cell Transfusion: A Case Report, Review of the Literature and Recommendation.Journal of clinical apheresis · 2026Review
- Use of Microbial Microarrays to Define Antibody Specificity.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Babesiosis and Malaria in the United States: Epidemiology, Research Funding, Medical Progress, & Recommendations for Improvement.Epidemiologia (Basel, Switzerland) · 2025Article
- Phenotype- and age-associated variations in non-specific agglutinins and complement components (C3 and C5a) in camels: Implications for transfusion compatibility and immune function.Veterinary world · 2025Article
- Circulating Immune Complexes and Glucose-6-Phosphate Dehydrogenase Deficiency Predict Recurrent Blackwater Fever in Ugandan Children With Severe Malaria.The Journal of infectious diseases · 2025Article
- ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies.iScience · 2023Review
- Decreased complement 4d increases poor prognosis in patients with non-small cell lung cancer combined with gastrointestinal lymph node metastasis.Experimental and therapeutic medicine · 2022Article
- Blood Transfusion Reactions-A Comprehensive Review of the Literature including a Swiss Perspective.Journal of clinical medicine · 2022Review
- Antibodies against biotin-labeled red blood cells can shorten posttransfusion survival.Transfusion · 2022Article
- Erythropoietic properties of human induced pluripotent stem cells-derived red blood cells in immunodeficient mice.American journal of hematology · 2022Article
- Evaluation of the Bactericidal Activity of Galectins.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Management of hemolytic transfusion reactions.Hematology. American Society of Hematology. Education Program · 2021Review
- Anti-JMH alloantibody in inherited JMH-negative patients leads to immunogenic destruction of JMH-positive RBCs.Clinical and experimental immunology · 2021Article
- Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.Blood advances · 2021Article
- Role of complement in alloimmunization and hyperhemolysis.Current opinion in hematology · 2020Review
- COVID-19 and the Coombs test.Blood · 2020Article
- Complement sC5b-9 and CH50 increase the risk of cancer-related mortality in patients with non-small cell lung cancer.Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Red blood cell (RBC) transfusion is a critical component of optimal management for a broad range of conditions. Regardless of the indication, pretransfusion testing is required to appropriately match RBC donors and recipients to provide immunologically compatible blood. Although this approach is effective in the vast majority of situations, occasionally, patients will inadvertently receive an incompatible RBC transfusion, which can result in a hemolytic transfusion reaction (HTR). In addition, patients with life-threatening anemia and a complex alloantibody profile, which precludes rapid procurement of compatible RBCs, may also receive incompatible RBCs, placing them at risk for an HTR. Despite the rarity of these clinical situations, when incompatible blood transfusion results in an HTR, the consequences can be devastating. In this review, we will explore the challenges associated with actively preventing and treating acute HTRs following incompatible RBC transfusion. In doing so, we will focus primarily on the role of complement, not only as a key player in HTRs, but also as a potential target for the prevention and treatment of HTRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.